Popular Trials
Corticosteroid
Ixazomib + Cyclophosphamide + Dexamethasone for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing cyclophosphamide given with ixazomib citrate and dexamethasone to see what effects, good and bad, it has in treating patients with previously untreated multiple myeloma or light chain amyloidosis.
Popular Filters
Trials for AL Amyloidosis Patients
Corticosteroid
Daratumumab Combination Therapy for Amyloidosis
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of four drugs on patients with a specific heart-related disease. The drugs work together to attack abnormal cells and reduce inflammation. The study aims to ensure the treatment is safe for the heart and understand how it behaves in different racial and ethnic groups.
Monoclonal Antibodies
Belantamab Mafodotin for AL Amyloidosis
Recruiting1 awardPhase 1 & 2
Stanford, California
This trial is testing Belantamab mafodotin, a drug that targets and kills harmful cells, on patients with Relapsed Refractory AL Amyloidosis who have not responded to other treatments. The drug works by attaching to bad cells and delivering a toxic substance to eliminate them. Belantamab mafodotin is a newly approved treatment for certain types of cancer.
Trials for ATTR Patients
Corticosteroid
Daratumumab Combination Therapy for Amyloidosis
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of four drugs on patients with a specific heart-related disease. The drugs work together to attack abnormal cells and reduce inflammation. The study aims to ensure the treatment is safe for the heart and understand how it behaves in different racial and ethnic groups.
Monoclonal Antibodies
Belantamab Mafodotin for AL Amyloidosis
Recruiting1 awardPhase 1 & 2
Stanford, California
This trial is testing Belantamab mafodotin, a drug that targets and kills harmful cells, on patients with Relapsed Refractory AL Amyloidosis who have not responded to other treatments. The drug works by attaching to bad cells and delivering a toxic substance to eliminate them. Belantamab mafodotin is a newly approved treatment for certain types of cancer.
Trials for TTR Positive Patients
Patisiran for Cardiomyopathy
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing a medication called patisiran. It aims to help people with a heart condition caused by abnormal protein buildup. The medication works by lowering the levels of these harmful proteins in the body. Patisiran has been shown to significantly reduce symptoms and improve quality of life in patients.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
Recruiting2 awardsPhase 3
San Diego, California
This trial is testing vutrisiran, an under-the-skin injection, in patients with a genetic condition called hATTR amyloidosis. The medication aims to lower harmful protein levels in their bodies. Vutrisiran is administered as a periodic subcutaneous injection.
Molecular Imaging Probe
[68Ga]CBP8 PET/MRI Imaging for Cardiac Amyloidosis
Recruiting1 awardPhase 3
Boston, Massachusetts
This trial will measure if a PET/MRI probe can detect heart fibrosis in people with cardiac amyloidosis. It will also compare the PET/MRI probe with standard MRI measures in people with and without heart disease.
Monoclonal Antibodies
ALXN2220 for ATTR-CM
Recruiting1 awardPhase 3
Irvine, California
This trial is testing a new drug called ALXN2220 to help adults with a heart condition known as ATTR-CM. The goal is to see if the drug can lower the risk of death and serious heart issues. Researchers are comparing the outcomes between those who receive the drug and those who do not.
Phase 3 Trials
Patisiran for Cardiomyopathy
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing a medication called patisiran. It aims to help people with a heart condition caused by abnormal protein buildup. The medication works by lowering the levels of these harmful proteins in the body. Patisiran has been shown to significantly reduce symptoms and improve quality of life in patients.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
Recruiting2 awardsPhase 3
San Diego, California
This trial is testing vutrisiran, an under-the-skin injection, in patients with a genetic condition called hATTR amyloidosis. The medication aims to lower harmful protein levels in their bodies. Vutrisiran is administered as a periodic subcutaneous injection.
Trials With No Placebo
Corticosteroid
Daratumumab Combination Therapy for Amyloidosis
Recruiting1 awardPhase 2
Duarte, California
This trial tests a combination of four drugs on patients with a specific heart-related disease. The drugs work together to attack abnormal cells and reduce inflammation. The study aims to ensure the treatment is safe for the heart and understand how it behaves in different racial and ethnic groups.
Monoclonal Antibodies
Belantamab Mafodotin for AL Amyloidosis
Recruiting1 awardPhase 1 & 2
Stanford, California
This trial is testing Belantamab mafodotin, a drug that targets and kills harmful cells, on patients with Relapsed Refractory AL Amyloidosis who have not responded to other treatments. The drug works by attaching to bad cells and delivering a toxic substance to eliminate them. Belantamab mafodotin is a newly approved treatment for certain types of cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.